These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16287807)

  • 1. Immune thrombocytopenia associated with efalizumab therapy for psoriasis.
    Warkentin TE; Kwon P
    Ann Intern Med; 2005 Nov; 143(10):761-3. PubMed ID: 16287807
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombocytopenia probably induced by acitretin.
    García-Arpa M; López-Nieto M; Santiago Sánchez-Mateos JL; Sánchez-Caminero MP
    Actas Dermosifiliogr; 2015 Oct; 106(8):692-3. PubMed ID: 26071907
    [No Abstract]   [Full Text] [Related]  

  • 3. Efalizumab-induced immune thrombocytopenia during retreatment.
    Fargnoli MC; Tabilio A; Coletti G; Peris K
    J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S125-7. PubMed ID: 18489048
    [No Abstract]   [Full Text] [Related]  

  • 4. Efalizumab-induced autoimmune pancytopenia.
    Tom WL; Miller MD; Hurley MY; Suneja T; Kudva G; Leonardi CL; Obadiah JM
    Br J Dermatol; 2006 Nov; 155(5):1045-7. PubMed ID: 17034539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efalizumab-associated thrombocytopenia.
    Hostetler SG; Zirwas M; Bechtel MA
    J Am Acad Dermatol; 2007 Oct; 57(4):707-10. PubMed ID: 17637485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
    Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
    J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
    [No Abstract]   [Full Text] [Related]  

  • 7. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 8. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
    de Groot M; de Rie MA; Bos JD
    Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
    [No Abstract]   [Full Text] [Related]  

  • 9. Efalizumab-induced thrombocytopenia: report of relapse after re-administration.
    Kiorpelidou D; Tsiouri G; Gaitanis G; Akritidis N; Bassukas ID
    Clin Exp Dermatol; 2009 Dec; 34(8):e914-6. PubMed ID: 20055866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efalizumab-induced aseptic meningitis.
    Kluger N; Girard C; Gonzalez V; Guillot B; Bessis D
    Br J Dermatol; 2007 Jan; 156(1):189-91. PubMed ID: 17199599
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple eruptive dermatofibromas in a patient receiving efalizumab.
    Santos-Juanes J; Coto-Segura P; Mallo S; Galache C; Soto J
    Dermatology; 2008; 216(4):363. PubMed ID: 18292655
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical experience with efalizumab in the Hospital of Cruces].
    Martínez de Lagrán Z; González Hermosa MR; Díaz-Pérez JL
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():74-81. PubMed ID: 18341856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efalizumab-induced lupus-like syndrome.
    Durox H; Sparsa A; Loustaud-Ratti V; Prey S; Gondran G; Manea P; Vidal E; Bedane C
    Acta Derm Venereol; 2008; 88(3):270-1. PubMed ID: 18480928
    [No Abstract]   [Full Text] [Related]  

  • 14. Migraine with aura induced by efalizumab.
    Kluger N; Heroum C; Michot C; Guillot B; Bessis D
    Clin Exp Dermatol; 2009 Oct; 34(7):e401-2. PubMed ID: 19549238
    [No Abstract]   [Full Text] [Related]  

  • 15. Recurrent angioedema associated with efalizumab.
    Mallbris L; von Bergen F; van Hage M; Ståhle M
    Acta Derm Venereol; 2009 Nov; 89(6):665-6. PubMed ID: 19997712
    [No Abstract]   [Full Text] [Related]  

  • 16. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
    Antonucci A; Bardazzi F; Balestri R; Patrizi A
    J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Final recommendations to incorporate efalizumab into the clinical practice].
    García-Díez A; Ferrándiz C
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():82. PubMed ID: 18341857
    [No Abstract]   [Full Text] [Related]  

  • 18. De novo onset of arthritis in patients previously treated with efalizumab: an observational case series.
    Colina M; Cianco G; Khodeir M; Sferra S; Scanavacca P; Corazza M; Virgili A; Trotta F
    Clin Exp Rheumatol; 2011; 29(1):141. PubMed ID: 21345301
    [No Abstract]   [Full Text] [Related]  

  • 19. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis-associated aseptic pneumonitis: another cause of lung involvement in psoriasis.
    Suárez-Amor O; Monteagudo B; Cabanillas M; Ramírez-Santos A
    Australas J Dermatol; 2014 Nov; 55(4):306. PubMed ID: 25399794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.